Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Olympus opts for Munich site for life sciences R&D (research and development) centre:

This article was originally published in Clinica

Executive Summary

Japanese camera and medical products developer Olympus has opted to locate its new life science research and development centre in Munich, Germany. Tokyo-based Olympus will invest some Euro15m ($21m) in the project, which will be opened officially in October. By 2009, it will be employing a staff of 450, who will be involved in production as well as R&D in the fields of molecular diagnostics, laboratory automation and digital processing in microscopy. Olympus' regional HQ, Olympus Europa Holding, is located in Hamburg. The proximity of the University Hospital Grosshadern to the new Bavarian site was an advantage, said Olympus regional executive managing director Dr Helmut Kohler. The group will be working in close co-operation with the hospital.

You may also be interested in...



US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

Oncology Drug Safety Is Key Focus In US FDA’s Generic Label Updates

US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.

EU GMP Annex I Proposal Would Maintain PUPSIT, Relax WFI Restrictions

The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.

Topics

UsernamePublicRestriction

Register

MT048542

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel